JP7653712B2 - 高リスク骨髄異形成症候群の治療薬 - Google Patents

高リスク骨髄異形成症候群の治療薬 Download PDF

Info

Publication number
JP7653712B2
JP7653712B2 JP2021565641A JP2021565641A JP7653712B2 JP 7653712 B2 JP7653712 B2 JP 7653712B2 JP 2021565641 A JP2021565641 A JP 2021565641A JP 2021565641 A JP2021565641 A JP 2021565641A JP 7653712 B2 JP7653712 B2 JP 7653712B2
Authority
JP
Japan
Prior art keywords
azacitidine
thiopurine
mercaptopurine
pharmaceutical
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021565641A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021125261A1 (enrdf_load_stackoverflow
Inventor
清行 緒方
由美 山元
Original Assignee
一般社団法人東京血液疾患研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 一般社団法人東京血液疾患研究所 filed Critical 一般社団法人東京血液疾患研究所
Publication of JPWO2021125261A1 publication Critical patent/JPWO2021125261A1/ja
Application granted granted Critical
Publication of JP7653712B2 publication Critical patent/JP7653712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021565641A 2019-12-18 2020-12-17 高リスク骨髄異形成症候群の治療薬 Active JP7653712B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019228026 2019-12-18
JP2019228026 2019-12-18
PCT/JP2020/047149 WO2021125261A1 (ja) 2019-12-18 2020-12-17 高リスク骨髄異形成症候群の治療薬

Publications (2)

Publication Number Publication Date
JPWO2021125261A1 JPWO2021125261A1 (enrdf_load_stackoverflow) 2021-06-24
JP7653712B2 true JP7653712B2 (ja) 2025-03-31

Family

ID=76477632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021565641A Active JP7653712B2 (ja) 2019-12-18 2020-12-17 高リスク骨髄異形成症候群の治療薬

Country Status (2)

Country Link
JP (1) JP7653712B2 (enrdf_load_stackoverflow)
WO (1) WO2021125261A1 (enrdf_load_stackoverflow)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204339A1 (en) 2001-04-24 2004-10-14 Dimartino Jorge F. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP2011520880A (ja) 2008-05-15 2011-07-21 セルジーン コーポレイション シチジン類似体の経口製剤およびその使用方法
JP2013526525A (ja) 2010-05-11 2013-06-24 セルジーン コーポレイション レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204339A1 (en) 2001-04-24 2004-10-14 Dimartino Jorge F. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP2011520880A (ja) 2008-05-15 2011-07-21 セルジーン コーポレイション シチジン類似体の経口製剤およびその使用方法
JP2013526525A (ja) 2010-05-11 2013-06-24 セルジーン コーポレイション レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Blood, The Journal of the American Society of Hematology，2019年，133.10，1086-1095
MIZOROGI F. et al.，Oral administration of cytarabine ocfosfate and 6-mercaptopurine in elderly patients at high risk fo，Jikeikai Med. J.，1998年，Vol.45/No.3，P.57-66
PILORGE S. et al.，The autommune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a re，British Journal of Haematology，2011年，Vol.153/No.5，P.664-665
WESNER N. et al.，Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective cas，Eur. J. Haematol.，2019年，Vol.102，P.63-69
久松理一，6-チオプリン/アザチオプリン，薬局，2016年，Vol.67/No.6，P.27-31，https://clinicaltrials.gov/ct2/show/NCT02706405
吉田篤史; 遠藤豊; 上野文昭，Trisomy8 を伴った骨髄異形成症候群に合併した小腸潰瘍，日本消化器内視鏡学会雑誌，2015年，57.2，170-171
押見和夫ほか，MDSにおける化学療法および分化誘導療法，医学のあゆみ，1991年，Vol.158/No.11，P.729-731

Also Published As

Publication number Publication date
WO2021125261A1 (ja) 2021-06-24
JPWO2021125261A1 (enrdf_load_stackoverflow) 2021-06-24

Similar Documents

Publication Publication Date Title
CA2926771C (en) Cancer treatment with combination of plinabulin and taxane
US9675631B2 (en) Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
RU2358730C2 (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
JP2006511538A (ja) 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用
WO2021037933A1 (en) Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
JP7653712B2 (ja) 高リスク骨髄異形成症候群の治療薬
JP6895688B2 (ja) 血液がんの新規治療法及び新規治療剤
US8124593B2 (en) Methods of treatment using sapacitabine
JP2025509278A (ja) 小細胞肺癌を治療する方法
JP2020537689A (ja) Ａ−ノル−５αアンドロスタン化合物を含む白血球増多製剤およびその使用
CA2742030A1 (en) Compositions and methods for treating myelodysplastic syndrome
AU2021227007A1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
EP2392329B1 (en) Compositions for use in treating myelodysplastic syndrome
US20210315898A1 (en) Combination therapy for treating cancer
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
TWI827864B (zh) 血液癌之新穎治療法及新穎治療劑
JP6486730B2 (ja) 骨髄異形成症候群の治療薬
US20220096508A1 (en) Method of treatment and pharmaceutical dosage form
CA3227813A1 (en) Pharmaceutical composition for treating solid tumors
KR20200094707A (ko) 셀레질린을 유효성분으로 포함하는 급성 골수성 백혈병의 예방 또는 치료용 약학 조성물
CN113350334A (zh) 一种含有双氢青蒿素的抗疟药物
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane
UA110606C2 (uk) Нове протипухлинне застосування кабазитакселу

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250311

R150 Certificate of patent or registration of utility model

Ref document number: 7653712

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150